Trials / Completed
CompletedNCT00847990
Non-Invasive Screening for Fetal Aneuploidy
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Sequenom, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Maternal blood screening test for fetal aneuploidy | One blood draw of 20 to 30 mL |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-04-01
- Completion
- 2011-08-01
- First posted
- 2009-02-20
- Last updated
- 2011-09-05
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00847990. Inclusion in this directory is not an endorsement.